10 Relapsing-Remitting Multiple Sclerosis (RRMS) Therapies

admin avatar

by admin |

Share this article:

Share article via email

Treating relapsing and remitting forms of multiple sclerosis requires a combination of cognitive and behavioral therapies, physiotherapy, lifestyle changes, and medication. Several pharmaceutical companies have clinical development plans in the works for the formulation of novel therapies to treat MS. Here are some of the available medications:

1. Aubagio (Oral)

news_16_Artboard 343 copy 156

Aubagio (chemically known as teriflunomide), marketed by Sanofi, is an active metabolite of the compound leflunomide and is a pyrimidine synthesis inhibitor.

Recently, researchers at the University of Texas Health Science Center at Houston, in collaboration with various institutions from north America and Europe, found that teriflunomide (Aubagio) is well-tolerated and efficient for the long-term treatment of multiple sclerosis (MS).

Read more about this study entitled “Long-term safety and efficacy of teriflunomide”.

2. Avonex (Injectable)

news_16_Artboard 343 copy 157

AVONEX (interferon beta-1a) by Biogen is a once-a-week treatment for relapsing multiple sclerosis (MS). Since it was approved in 1996, it has been prescribed to over 455,000 people.

Want to stay update with Avonex most recent news?

3. Lemtrada (Infused)

news_16_Artboard 343 copy 158

Lemtrada, manufactured by Genzyme (a Sanofi company), is a disease modifying therapy for people with relapsing-remitting forms of multiple sclerosis (RRMS).

A recent study of relapsing-remitting multiple sclerosis (RRMS) patients who had one or more relapses on earlier treatment, showed that alemtuzumab (Lemtrada) improved disability progression over five years, even though most patients received treatment only during the first two years.

Read more about the results that were presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting.

4. Betaseron/Betaconnect (Injectable)

news_16_Artboard 343 copy 159

In 1993, Bayer’s Betaseron (interferon beta-1b) became the first disease-modifying drug to be approved by the U.S. Food and Drug Administration (FDA) for patients with relapsing forms of multiple sclerosis (MS) after the first MS event.

Recently, the first and only electronic autoinjector for Betaseron administration in relapsing-remitting MS (RRMS), called Betaconnect, was also granted FDA approval. This allows for a more customized injection and therapy delivery.

Watch the interview with Bayer’s vice president and general manager for MS Business, Klaus Marten, discussing the therapeutic advantages of both Betaseron and Betaconnect.

5. Novantrone (Infused)

news_16_Artboard 343 copy 160

According to the National MS Society, before Novantrone (mitoxantrone) was approved for use against MS, it was used only to treat certain forms of cancer.

“It acts in MS by suppressing the activity of T cells, B cells, and macrophages that are thought to lead the attack on the myelin sheath.”

Want to stay update with Novantrone most recent news?

6. Copaxone (Injectable)

news_16_Artboard 343 copy 161

Glatiramer acetate, manufactured and marketed under the name Copaxone by Teva Pharmaceuticals, is an immunomodulatory injectable drug used for combating the symptoms of multiple sclerosis (MS) in patients.

Want to stay update with Copaxone most recent news?

7. Tecfidera (Oral)

news_16_Artboard 343 copy 162

Tecfidera is an oral medication and although this medication is not completely understood, researchers believe that Tecfidera inhibits immune system cells and molecules.

Biogen recently reported new data showing the effectiveness of Tecfidera (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients.

8. Plegridy (Injectable)

news_16_Artboard 343 copy 163

Peginterferon beta-1a, known by its brand name Plegridy, is an approved treatment for relapsing and remitting forms of multiple sclerosis (RRMS).

About a year ago,  Plegridy by Biogen Idec, received Welsh NHS approval following NHS Scotland’s approval earlier that year. Plegridy was approved across several countries in the European Union in July of 2014.

Read other Plegridy related news here. 

9. Gilenya (Oral)

news_16_Artboard 343 copy 164

Fingolimod, a drug manufactured by Novartis under the brand name Gilenya, is a U.S. Food and Drug Administration (FDA)-approved treatment for symptoms of relapsing forms of multiple sclerosis (MS).

A recent study reported that Fingolimod (Gilenya) may also help these patients by directly enhancing nerve regeneration and increasing myelination in a way that is partly independent of its anti-inflammatory properties.

10. Tysabri (Infused)

news_16_Artboard 343 copy 165

Natalizumab (manufactured by Biogen Idec as Tysabri; previously named Antegren) is a humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) as a monotherapy for the treatment of relapsing-remitting forms of multiple sclerosis (MS), and of Crohn’s disease.

Recently, results from the STRIVE study supported the safety of natalizumab (Tysabri) as a therapy for multiple sclerosis (MS) patients. 

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.